ABSTRACT
Immunoglobulin A (IgA) nephropathy poses many challenges to investigators and physicians in its etiology, pathogenesis, prevention, and treatment. But at the same time, opportunities abound for new tests and treatments that may eventually lead to control of this common form of chronic kidney disease.
Footnotes
↵* The author has disclosed that he has received consulting fees from the Aspreva, Genentech, Keryx, and Novartis corporations.
- Copyright © 2008 The Cleveland Clinic Foundation. All Rights Reserved.
